Back to Stocks

KRRO

Korro Bio, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Korro Bio has successfully transitioned from a broad, cash-intensive expansion phase to a disciplined, clinically focused enterprise. The company's recent financial results highlight a significant reduction in operational burn, with R&D expenses falling 34% year-over-year.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a 'disciplined' pivot, Korro Bio faces severe concentration risk. The termination of the KRRO-110 program following a failure to reach projected protein levels in Phase 1/2a trials underscores the inherent volatility of the RNA-editing platform.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every KRRO filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Korro Bio is currently a binary bet on the viability of its OPERA RNA-editing platform, specifically the KRRO-121 program. The 10-Q reveals a company that has successfully bought itself time through aggressive cost-cutting and strategic capital raises, but has simultaneously narrowed its path to success. The transition from LNP to GalNAc-conjugated delivery across its pipeline is a critical technical pivot that must be validated in human trials to prove the platform's efficacy. Investors are now weighing a fortified balance sheet against a depleted pipeline. The core tension lies in whether the capital efficiency achieved in Q1 2026 is a sustainable strategic shift or a desperate measure to survive until the next clinical data point. The upcoming 2026 IND filing for KRRO-121 and the nomination of an AATD development candidate in Q2 2026 will be the definitive catalysts that determine if Korro is a leader in precision genetic medicine or a cautionary tale of platform failure.

Selected Quarter

Core Takeaway

Korro has traded pipeline breadth for financial survival, concentrating all remaining resources on KRRO-121 to reach a 2026 clinical inflection point.

Investor Lens

The trade-off is between a secure 3-year cash runway and the binary risk of a single-asset pipeline.

Watch Next

The nomination of the AATD development candidate in Q2 2026 and the KRRO-121 IND filing in H2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.33Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise
90%
bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion
60%
bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss
50%
bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise
90%
bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion
60%
bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss
50%
bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise
90%
bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion
60%
bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss
50%
bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise
90%
bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion
60%
bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss
50%
bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise
90%
bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion
60%
bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss
50%
bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise
90%
bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion
60%
bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss
50%
bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise
90%
bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion
60%
bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss
50%

Filing History

10-QMay 7, 2026
Expand Sequence

Korro Bio is currently a binary bet on the viability of its OPERA RNA-editing platform, specifically the KRRO-121 program. The 10-Q reveals a company that has successfully bought itself time through aggressive cost-cutting and strategic capital raises, but has simultaneously narrowed its path to success. The transition from LNP to GalNAc-conjugated delivery across its pipeline is a critical technical pivot that must be validated in human trials to prove the platform's efficacy. Investors are now weighing a fortified balance sheet against a depleted pipeline. The core tension lies in whether the capital efficiency achieved in Q1 2026 is a sustainable strategic shift or a desperate measure to survive until the next clinical data point. The upcoming 2026 IND filing for KRRO-121 and the nomination of an AATD development candidate in Q2 2026 will be the definitive catalysts that determine if Korro is a leader in precision genetic medicine or a cautionary tale of platform failure.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.